Clinical Trial

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program

All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients The first group of participants reached…

2 months ago

LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced…

2 months ago

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study

HAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab’s…

2 months ago

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100…

2 months ago

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical…

2 months ago

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

Quarterly Revenue Growth of 13% to ~$68 Million  Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class…

2 months ago

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of…

2 months ago

The Michael J. Fox Foundation for Parkinson’s Research Applauds Texas Voters on Passage of Proposition 14 Securing $3 Billion for Brain Disease Research

The ballot measure was supported by national and local neurodegenerative disease organizations, including The Michael J. Fox Foundation (MJFF). MJFF…

2 months ago

Top 5 Global CRO Chooses RealTime eClinical Solutions to Modernize Regulatory Oversight Across Hundreds of Studies

SAN ANTONIO, Nov. 5, 2025 /PRNewswire/ -- RealTime eClinical Solutions, a leader in clinical research software technology, today announced that…

2 months ago